Pfizer Inc. $PFE Shares Bought by BNP Paribas

BNP Paribas lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 85.8% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 635,974 shares of the biopharmaceutical company’s stock after purchasing an additional 293,744 shares during the quarter. BNP Paribas’ holdings in Pfizer were worth $15,842,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently made changes to their positions in PFE. Norges Bank purchased a new position in Pfizer in the fourth quarter valued at $1,830,986,000. Franklin Resources Inc. increased its stake in shares of Pfizer by 47.8% during the third quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company’s stock worth $638,787,000 after purchasing an additional 8,108,887 shares in the last quarter. Vanguard Group Inc. boosted its position in Pfizer by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock worth $13,479,520,000 after acquiring an additional 7,031,162 shares during the last quarter. Neuberger Berman Group LLC boosted its position in Pfizer by 203.8% during the third quarter. Neuberger Berman Group LLC now owns 9,012,811 shares of the biopharmaceutical company’s stock worth $229,346,000 after acquiring an additional 6,045,763 shares during the last quarter. Finally, Ameriprise Financial Inc. boosted its position in Pfizer by 48.2% during the third quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company’s stock worth $468,174,000 after acquiring an additional 5,978,927 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer announced a global oncology partnership with Innovent Biologics worth up to $10.5 billion, giving it access to 12 early-stage cancer programs and expanding its pipeline in high-value areas like antibody-drug conjugates and multispecific antibodies. Pfizer Oncology Deal And Lung Cancer Data Reshape Valuation Debate
• Positive Sentiment: Pfizer also reported encouraging seven-year follow-up data from its Phase 3 CROWN trial, showing sustained protection from LORBRENA against disease progression and brain metastases in ALK-positive advanced lung cancer. Pfizer Oncology Deal And Lung Cancer Data Reshape Valuation Debate
• Positive Sentiment: Pfizer said its BRAFTOVI-based regimen nearly doubled median progression-free survival in previously untreated metastatic colorectal cancer, another data point that strengthens the company’s cancer franchise. Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer
• Neutral Sentiment: Pfizer invited investors to a webcast with CEO Albert Bourla at the Goldman Sachs Healthcare Conference on June 8, which is a routine investor-relations update rather than a major catalyst. Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
• Neutral Sentiment: Foundation Medicine received FDA approvals for companion diagnostics tied to Pfizer’s TALZENNA/XTANDI prostate cancer regimen, supporting commercialization but not changing the core investment thesis on its own. US FDA Approves FoundationOne CDx and FoundationOne Liquid CDx as Companion Diagnostics for TALZENNA
• Negative Sentiment: Some market commentary continues to frame Pfizer as a potential value trap, and analysts remain cautious because the stock has underperformed peers and is still rebuilding growth after its pandemic-era peak. How Is Pfizer’s Stock Performance Compared to Other Healthcare Stocks?

Pfizer Price Performance

Shares of PFE opened at $25.62 on Tuesday. Pfizer Inc. has a fifty-two week low of $23.06 and a fifty-two week high of $28.75. The firm’s 50 day moving average price is $26.73 and its 200 day moving average price is $26.30. The company has a market cap of $146.01 billion, a P/E ratio of 19.56 and a beta of 0.34. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. During the same period in the prior year, the firm earned $0.92 EPS. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts forecast that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.7%. Pfizer’s dividend payout ratio is currently 131.30%.

Analyst Ratings Changes

PFE has been the topic of a number of recent research reports. Cantor Fitzgerald restated a “neutral” rating on shares of Pfizer in a research report on Monday. CICC Research initiated coverage on shares of Pfizer in a report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 target price on the stock. Guggenheim boosted their target price on shares of Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. Morgan Stanley boosted their target price on shares of Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a report on Friday, April 10th. Finally, Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, eleven have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $28.82.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.